What could possibly go wrong with a fast-tracked vaccine?
Moderna COVID Vaccine Trial Sees 20% “Serious” Injury Rate as U.S. Invests BILLIONS More on Experimental COVID Vaccines
The vaccine, developed and championed by Anthony Fauci and financed by Bill Gates, used an experimental mRNA technology that the two men hoped would allow rapid deployment to meet President Trump’s ambitious “warp speed” time line. Dr. Fauci was so confident of his shot’s safety that he waived ferret and primate studies (Moderna suspiciously reported no specific health data from its mouse studies). That appears to have been a mistake.
Moderna did not release its clinical trial study or raw data, but its press release, which was freighted with inconsistencies acknowledged that three volunteers developed Grade 3 systemic events defined by the FDA as “Preventing daily activity and requiring medical intervention.”
Moderna allowed only exceptionally healthy volunteers to participate in the study. A vaccine with those reaction rates could cause grave injuries in 1.5 billion humans if administered to “every person on earth”.
That is the threshold that Gates has established for ending the global lockdown. Moderna did not explain why it reported positive antibody tests for only eight participants.
These outcomes are particularly disappointing because the most hazardous hurdle for the inoculation is still ahead; challenging participants with wild COVID infection.
Past attempts at developing COVID vaccines have always faltered at this stage as both humans and animals achieved robust antibody response then sickened and died when exposed to the wild virus.
Moderna unveiled encouraging coronavirus vaccine results. Then top execs dumped nearly $30 million of stock
Moderna’s stock price skyrocketed as much as 30% on Monday after the biotech company announced promising early results for its coronavirus vaccine. As ordinary investors piled in, two insiders were quietly heading for the exits.Moderna’s chief financial officer and chief medical officer executed options and sold nearly $30 million of shares combined on Monday and Tuesday, SEC filings reviewed by CNN Business show.
Moderna stock then proceeded to fall over the next few days as scientists excoriated the company for not presenting the data to back up its promising vaccine progress claims. It’s now back to the same price it was at previous to the announcement.
A classic pump-and-dump?
Maybe. Maybe not. But man, the optics on this are terrible…